The 3.2% placebo-adjusted weight loss fell short of the 8-10% analysts expected, raising questions about Ionis's metabolic pivot. The stock trades at a discount ahead of the February olezarsen decision.
Ionis Pharmaceuticals shares fell 12% on Wednesday after the company reported that its experimental obesity drug, IONIS-656, failed to meet the primary endpoint in a Phase 2 trial. The once-weekly injection produced a placebo-adjusted weight reduction of 3.2% at 36 weeks. Analysts had modeled weight loss in the 8-10% range.
The miss lands at a delicate moment for Ionis. The company has been repositioning itself as a metabolic-disease player after years of dominance in rare neurological disorders. Its lead pipeline candidate, olezarsen for familial chylomicronemia syndrome, is on track for an FDA decision in the first quarter of 2027. The obesity setback raises questions about Ionis's ability to compete in weight-loss indications dominated by GLP-1 drugs.
Chief Medical Officer Dr. Sarah Chen said on the investor call that the company would analyze the full dataset before deciding on next steps for IONIS-656. "The weight loss we observed was statistically significant. It was not clinically competitive at the dose tested," she said. "We need to understand whether a higher dose or a different dosing schedule could bridge the gap."
Analysts reacted with skepticism. Jefferies analyst Michael Yee wrote in a note that the data "effectively ends the program as a standalone obesity therapy." Yee said Ionis would need to show a path to 8% or greater weight loss to justify further investment. The stock sits 28% below its 52-week high set in June.
The setback does not affect Ionis's near-term regulatory catalysts. The olezarsen PDUFA date in February 2027 remains the most significant value driver, with consensus peak sales estimates of $1.2 billion. The company also has a Phase 3 readout for donidalorsen in hereditary angioedema expected in the fourth quarter of this year.
Ionis ended the second quarter with $2.1 billion in cash and investments, giving it runway through multiple catalysts without needing to raise capital. The stock trades at 3.2 times forward sales, a discount to the biotech sector median of 5.1 times, reflecting market skepticism about the pipeline beyond olezarsen. AlphaScala has not assigned a score to IONS given the binary nature of the upcoming data.
What would change the narrative is a positive olezarsen label or a partnership deal for the obesity program that validates the antisense platform. Ionis has a history of licensing its technology to larger partners, including Biogen and Novartis. Chen did not rule out seeking a collaborator for IONIS-656. "We are open to partnerships that maximize the value of our metabolic pipeline," she said.
The donidalorsen readout in HAE is expected by year-end. A positive result would give investors more confidence in the pipeline beyond olezarsen, analysts said. Ionis has enough cash to reach both milestones without a capital raise. The olezarsen PDUFA date is February 2027.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.